Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2010-07-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm100189aPMID 20925433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New insights into small‐molecule inhibitors of Bcr‐Abl

  2011cited by this paper
• Gateways to clinical trials.

  2010cited by this paper
• Genomics in Leukemias

  2010cited by this paper
• Heat shock protein 90: inhibitors in clinical trials.

  2010cited by this paper
• Molecular Signatures of Quiescent, Mobilized and Leukemia-Initiating Hematopoietic Stem Cells

  2010cited by this paper
• Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

  2010cited by this paper
• Leukaemogenesis: more than mutant genes

  2010cited by this paper
• Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.

  2009cited by this paper
• Differentiation therapy of leukemia: 3 decades of development.

  2009cited by this paper
• Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.

  2009cited by this paper
• The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line

  2009cited by this paper
• Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes

  2009cited by this paper
• Pazopanib: therapeutic developments

  2009cited by this paper
• Development of cell-cycle inhibitors for cancer therapy

  2009cited by this paper
• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

  2009cited by this paper
• PTEN, Stem Cells, and Cancer Stem Cells*

  2009cited by this paper
• Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.

  2009cited by this paper
• Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.

  2009cited by this paper
• Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy.

  2009cited by this paper
• Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

  2009cited by this paper
• Curcumin is a potent DNA hypomethylation agent.

  2009cited by this paper
• Rendering the leukemia cell susceptible to attack.

  2009cited by this paper
• Discovery and development of aurora kinase inhibitors as anticancer agents.

  2009cited by this paper
• FLT3 inhibition as a targeted therapy for acute myeloid leukemia

  2009cited by this paper
• Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes.

  2009cited by this paper
• KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

  2009cited by this paper
• Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

  2009cited by this paper
• mTOR signaling at a glance

  2009cited by this paper
• Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

  2009cited by this paper
• Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

  2009cited by this paper
• Pharmacogenetics in acute lymphoblastic leukemia.

  2009cited by this paper
• Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

  2009cited by this paper
• The promises and pitfalls of epigenetic therapies in solid tumours.

  2009cited by this paper
• Erythropoiesis: Model systems, molecular regulators, and developmental programs

  2009cited by this paper
• Epigenetic therapies in haematological malignancies: searching for true targets.

  2009cited by this paper
• Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients

  2009cited by this paper
• Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

  2009cited by this paper
• Pharmacogenomics of Dasatinib (Sprycel

  2009cited by this paper
• IFNα activates dormant haematopoietic stem cells in vivo

  2009cited by this paper
• Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

  2009cited by this paper
• BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

  2009cited by this paper
• Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

  2009cited by this paper
• DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

  2009cited by this paper
• Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

  2009cited by this paper
• Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.

  2009cited by this paper
• MonitorMoleculesOrally bioavailable proteasome inhibitors: preclinical development of PR-047

  2009cited by this paper
• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  2009cited by this paper
• Kinase domain mutations in cancer: implications for small molecule drug design strategies.

  2009cited by this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cited by this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cited by this paper
• Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

  2009cited by this paper
• Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

  2009cited by this paper
• First‐line therapy for chronic myeloid leukemia: Past, present, and future

  2009cited by this paper
• Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

  2009cited by this paper
• The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

  2009cited by this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cited by this paper
• The leukemic stem cell niche: current concepts and therapeutic opportunities.

  2009cited by this paper
• BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

  2008cited by this paper
• A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

  2008cited by this paper
• Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1.

  2008cited by this paper
• New molecular concepts and targets in acute myeloid leukemia

  2008cited by this paper
• Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

  2008cited by this paper
• Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery.

  2008cited by this paper
• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  2008cited by this paper
• A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells

  2008cited by this paper
• Activation of tyrosine kinases by mutation of the gatekeeper threonine

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• BCL-2 family antagonists for cancer therapy

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.

  2008cited by this paper
• Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.

  2008cited by this paper
• Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer.

  2008cited by this paper
• Chronic myeloid leukemia stem cells.

  2008cited by this paper
• Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation

  2008cited by this paper
• sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.

  2008cited by this paper
• CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines

  2008cited by this paper
• Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

  2008cited by this paper
• AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.

  2008cited by this paper
• Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

  2008cited by this paper
• mTOR Inhibitors in Oncology

  2008cited by this paper
• A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

  2008cited by this paper
• Small molecules ATP-competitive inhibitors of FLT3: a chemical overview.

  2008cited by this paper
• Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.

  2008cited by this paper
• Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate.

  2008cited by this paper
• Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction

  2008cited by this paper
• Histone deacetylase inhibitors: from bench to clinic.

  2008cited by this paper
• Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

  2008cited by this paper
• Locked nucleic acid holds promise in the treatment of cancer.

  2008cited by this paper
• Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model

  2008cited by this paper
• Mammalian target of rapamycin as a target in hematological malignancies.

  2008cited by this paper
• Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

  2008cited by this paper
• Experimental non-ATP-competitive therapies for chronic myelogenous leukemia

  2008cited by this paper
• The therapeutic potential of the proteasome in leukaemia

  2008cited by this paper
• CDK inhibitors in cancer therapy: what is next?

  2008cited by this paper
• Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.

  2008cited by this paper
• Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

  2008cited by this paper
• Why is cancer drug discovery so difficult?

  2007cited by this paper
• Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.

  2007cited by this paper
• Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

  2007cited by this paper
• BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

  2007cited by this paper

• Revealing the Binding Mechanism of Gossypol on Bcl‑2 via Funnel Metadynamics Simulations.

  2026cites this paper
• Unraveling Drug Response from Pharmacogenomic Data to Advance Systems Pharmacology Decisions in Tumor Therapeutics

  2022cites this paper
• Isobavachalcone inhibits acute myeloid leukemia: Potential role for ROS‐dependent mitochondrial apoptosis and differentiation

  2021influential citation
• Z-Ligustilide Selectively Targets AML by Restoring Nuclear Receptors Nur77 and NOR-1-mediated Apoptosis and Differentiation.

  2020cites this paper
• Synthesis and Characterization of Some Novel Hydrazones of N-{11H-pyrido[2,1-b]quinazolin-11-one-9-yl} hydrazine

  2019cites this paper
• 4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth

  2019cites this paper
• Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells.

  2018cites this paper
• Design and Synthesis of C3‐Substituted β‐Carboline‐Based Histone Deacetylase Inhibitors with Potent Antitumor Activities

  2017cites this paper
• Canthin-6-one induces cell death, cell cycle arrest and differentiation in human myeloid leukemia cells.

  2017cites this paper
• Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).

  2016cites this paper
• Synthesis, antitumor activity and preliminary structure-activity relationship of 2-aminothiazole derivatives

  2016cites this paper
• Synthesis and anti-proliferative activity of pyridine O-galactosides and 4-fluorobenzoyl analogues

  2015cites this paper
• Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned

  2014cites this paper
• Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.

  2013cites this paper
• Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.

  2012cites this paper
• Toddaculin, a natural coumarin from Toddalia asiatica, induces differentiation and apoptosis in U-937 leukemic cells.

  2012cites this paper
• Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides.

  2012cites this paper
• Cyclin-Dependent Kinase Modulators and Cancer Therapy

  2012cites this paper
• Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery

  2012cites this paper
• Cyclin-dependent kinase modulators and cancer therapy.

  2012cites this paper
• Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements.

  2012cites this paper
• Synthesis and Cytotoxicity Studies of Novel 2‐Hydrazonylpyrido[2,3‐b]pyrazin‐3(4H)‐ones

  2012cites this paper
• Pharmacogenomics and Nanotechnology Toward Advancing Personalized Medicine

  2012cites this paper
• Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery

  2012cites this paper
• Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes.

  2011cites this paper
• Designed multiple ligands for cancer therapy.

  2011cites this paper
• MeSHy: Mining unanticipated PubMed information using frequencies of occurrences and concurrences of MeSH terms

  2011cites this paper